InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
RedStick Free
03/12/09 11:34 AM
profile icon
surf1944 Free
05/18/07 8:32 AM
profile icon
surf1944 Free
04/25/07 7:35 AM
profile icon
surf1944 Free
03/27/07 11:50 PM
profile icon
Cashoutfl Free
03/27/07 11:40 PM
profile icon
surf1944 Free
03/26/07 5:42 PM
profile icon
Bull Trader Free
03/23/07 8:03 PM
profile icon
surf1944 Free
03/23/07 5:56 PM

CV Therapeutics, Inc. (CVTX) RSS Feed

Followers
0
Posters
4
Posts (Today)
0
Posts (Total)
8
Created
03/23/07
Type
Free
Moderators
http://www.cvt.com/ http://finance.yahoo.com/q/h?s=CVTX CV Therapeutics, Inc., a biopharmaceutical company, focuses on applying molecular cardiology to the discovery, development, and commercialization of small molecule drugs for the treatment of cardiovascular diseases. Its approved product, Ranexa (ranolazine extended-release tablets) is indicated for the treatment of chronic angina. The company also develops Ranexa, which is in Phase III clinical development stage for the treatment of acute coronary syndrome. In addition, it has other clinical and preclinical drug development candidates and programs, including Regadenoson, which is in Phase III clinical development stage for use as a pharmacologic stress agent in myocardial perfusion imaging studies; Tecadenoson, a selective A1-adenosine receptor agonist for the reduction of rapid heart rate during acute atrial arrhythmias, which is in Phase III clinical development stage; Adentri, which is in Phase II clinical development stage for the treatment of heart failure; and CVT-6883 that is in Phase I clinical development stage for the treatment of cardiopulmonary disease. Further, the company?s preclinical drug development candidates and programs include Adenosine receptors for atrial arrhythmias, lipid metabolism, diabetes, metabolic syndrome, dyslipidemia, and addiction; Late sodium current for ischemic conditions; and reverse cholesterol transport for atherosclerosis. CV Therapeutics has strategic alliances with Roche Palo Alto LLC; Biogen Idec, Inc.; Astellas Pharma, Inc.; and PTC Therapeutics, Inc. The company was founded in 1990 and is headquartered in Palo Alto, California. Gallery View 4: (Full Sto, MACD, Aroon8)
Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
CVTX Latest News
  • No Recent News Available for this company!
New Post